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In a practical environment, veterinarians estimate the prevalence of mastitis on a dairy 
farm using the Equation:  
            
(                                                  )
                          
 
Thus, the prevalence of mastitis at any given time depends on the duration of each 
intramammary infection and the number of infected cows. Effective mastitis control 
programs rely on decreasing the risk of exposure to mastitis-causing organisms 
(MCOs) and elimination of existing infections. Cows affected by clinical and/or 
subclinical mastitis are an obvious source of cross-infection to herd mates (regardless 
of whether the pathogens were contagious or environmental in origin). Therefore, 
minimising exposure of healthy cows during the shedding phase of infected cows can 
reduce the potential risk of new infection, and is one avenue of approaching mastitis 
control. Shortening or cessation of the shedding phase can be achieved by different 
means, including temporary or permanent removal of the infected cow/s from residence 
within the ‘healthy’ herd, pre-term drying off (extending the dry phase) and lactational 
or dry cow treatment. Mastitis treatment and its failure, with an emphasis on 
antimicrobial therapy, are the main focus of this paper. Pharmacokinetic properties of 
the product formulation used for mastitis treatment are not discussed. 
The successful use of antimicrobial drugs for mastitis treatment depends on the same 
basic principles that apply to all microbial infections:  
1. Selecting an antimicrobial agent that is effective against the target MCOs. 
2. Attaining and maintaining therapeutic concentrations of the drug at the infection 
site until the infective MCOs are suppressed and/or inhibited. 
3. Minimising local or systemic side effects of therapy, and  
4. Coordinated administration of supportive, non-antimicrobial therapies as 
considered relevant in each case1. 
Despite an appropriate choice of antimicrobial, mastitis treatment often fails. Current 
treatments used for clinical mastitis during lactation often have a poorer cure rate than 
predicted by in vitro susceptibility, especially in cases of mastitis caused by 
Staphylococcus aureus which, as a chronic infection, is responsible for huge economic 
losses. Bacteriological cure of S. aureus infections during lactation has been estimated 
at a rate of only 25% - 50%. Antimicrobial resistance of MCOs is commonly not the 
predominant factor in treatment failure2, 3. The explanation for unsuccessful treatment 
outcomes must therefore be elucidated from other factors which contribute toward 
therapy efficacy.  
There are four major groups of factors associated with bovine mastitis treatment failure: 
1. Management and iatrogenic factors 
  
 
2. Drug factors 
3. Mastitis-causing organism factors, and 
4. Mammary gland factors. 
Additionally, herd, cow and quarter level factors can also affect the results of bovine 
mastitis treatment. 
Management and iatrogenic factors 
Many management and iatrogenic factors can be the reason for mastitis treatment 
failure. Commonly listed include: 
 inaccurate diagnosis 
 delayed initial treatment 
 improper dose or treatment regime 
 improper route of administration, 
 depth of insertion of the infusion cannula  
 duration of treatment 
 inadequate supportive treatment, and 
 failure to ensure treatment is performed according to best practice, e.g. in 
suitably aseptic conditions   
Inaccurate diagnosis, delayed initial treatment and assessment of cure 
Quality and precision of mastitis diagnostics, and time elapsed between diagnosis and 
treatment initiation are important factors affecting the cure rate of intramammary 
infections. In many countries, excluding the Nordic countries of Europe, mastitis 
diagnosis and antimicrobial treatments are responsibilities assigned to farm personnel. 
Treatment of mastitis in such cases is often empirically based on a presumptive cause 
and perceptions of historical efficacy. Inaccurate diagnoses (i.e. over-diagnosing, 
treating sub-clinical mastitis as clinical, and teat canal infections) lead to inappropriate 
therapy and consequently, to overuse of antimicrobials. Overuse of antimicrobials is 
associated with an increased risk of development of broad-scale antimicrobial 
resistance and unnecessary loss of milk/income. 
To decrease the risk of failure, treatment of mastitis should commence immediately 
upon appearance of clinical signs. Prompt treatment inhibits the progression of invasive 
mastitis (i.e. becoming chronic or abscess-forming) and increases treatment success 
rates4. Failure to treat mastitis early increases risk of treatment failure as some MCOs 
transgress from the gland, into the protected environment within cells including 
mammary epithelial cells and neutrophils.  Additionally, accurately defining a ‘cured’ 
status in the field is largely circumstantial and presumptive. Therefore, the perception 
of farm personnel of ‘how well’ a particular treatment works on a given farm can be 
misleading, with antimicrobials frequently used without valid justification. 
In many cases, particularly with staphylococcal (e.g. S. aureus) and some 
streptococcal (e.g. Streptococcus uberis) infections, mastitis treatment results in a 
clinical cure but microbiological cure is not achieved. At present, diagnostic 
methodologies for bovine mastitis are not technically rigorous, and translation from a 
clinical to a subclinical state is often mistakenly considered as a cure.  
In the assessment of cure and repeated cases, the principles of super-infection and re-
infection are important. Super-infection can occur during intramammary treatment if the 
cannula is contaminated or there is poor sanitation of the teat end prior to treatment. 
Often, the secondary intramammary infection, caused by the newly introduced 
organisms, results in a worse clinical implication than if no intramammary treatment 
was administered at all, particularly if the new MCOs are Pseudomonas aeruginosa, 
Candida spp, and Nocardia spp. Re-infection of treated quarters is a common 
  
 
explanation for failure of the mastitis treatment in practice, and in studies reporting 
efficacy of products for treatment of mastitis. The mechanisms promoting re-infection 
can be summarised as: 
1. Treatment or the mammary defence mechanisms were not sufficiently effective. 
Thus, an inoculum of MCO has remained. 
2. Trauma of the teat canal or teat end. This will be discussed later. 
3. Advancement into deeper/higher recesses of the gland by the MCOs. The 
ultimate potential for vertical dispersal and penetration by the antimicrobial in 
the upper parts of the mammary gland is poor. This is compounded by cytotoxic 
effects which incite a local inflammatory reaction.  
4. Increased susceptibility of the gland to re-infection. This will be discussed later. 
Prevention: Bovine practitioners should educate their clients of the: 
 importance of accurate diagnosis 
 importance of prompt and appropriate treatment 
 differentiation of sub-clinical and clinical mastitis 
 differentiation of teat canal infection and clinical mastitis 
 concepts of super-infection and re-infection, and  
 assessment of treatment outcomes 
The best approach to improved treatment outcomes and general mastitis management  
is a combination of maintaining good, ongoing communication with dairy clients about 
their farms’ current udder health status, and regular focus events (usually semi-
annually or annually), e.g. discussion groups or farm-based short seminars. 
Improper dose and route of administration, depth of insertion of infusion 
cannula and duration of treatment 
The success of antimicrobial therapy depends on early intervention which results in 
appropriate drug concentration at the infection site. Thus, administering a lower dose 
than required or parenteral administration in a dehydrated or shocked cow is 
unadvisable. This scenario can lead to low drug concentration at the site of infection, 
below the minimum inhibitory concentration (MIC). It is worth mentioning that the dose 
of antimicrobial within currently commercially available intramammary preparations 
may now need some revision. Many of these products were first registered in the 
1970s and 1980s. Dairy cows of that era produced less than half of what they do today. 
Additionally, the dose of antimicrobial used in intramammary preparations should follow 
susceptibility changes which influence MICs of mastitis pathogens. Unfortunately, no 
dosage adjustment in these antimicrobial products has been made, in light of increased 
milk volume production or changes in the MICs. 
Pharmacological treatment of bovine mastitis can be administered intramammary or 
systemically. Systemic treatment is generally parenteral, to avoid disturbance to the 
rumen and gastro-intestinal micro flora. Following intramammary administration, the 
concentration of antimicrobial in the milk compartment of the mammary gland is 
expected to be higher. These higher concentrations are achieved using smaller 
amounts of the active substance, as the drug is administered directly to the infection 
site. The intramammary route of administration is preferential for the treatment of mild 
cases of mastitis which don’t result in ‘sick-cow syndrome’5). In practice, the 
intramammary route of administration is used when one or two quarters in the same 
cow are concurrently affected. Parenteral therapy becomes a recommended addition to 
the treatment regime when significant oedema or inflammation is a feature of mastitis. 
The potential swelling-associated occlusion of milk ducts may impede the distribution of 
intramammary administered antimicrobials1, 6. Additionally, parenteral treatment should 
be used when the general health of the cow is impaired1, 5. In practice, the parenteral 
  
 
route of administration is also preferentially used when two or more quarters are 
affected at the same time. 
Pharmacokinetics of the active requires some consideration when selecting the route of 
antimicrobial therapy. In particular, parenteral therapy requires administration of higher 
doses of the antimicrobial active due to distribution of the drug throughout the body of 
the cow, prior to reaching the mammary gland via the bloodstream. A combined 
treatment approach (concurrent administration of antimicrobials by intramammary and 
parenteral route) may insure somewhat against achieving only sub-therapeutic 
concentrations of the active at the infection site. Therefore, it is a commonly used 
treatment tactic for mastitis that features swollen, hard quarters, or when treating 
repetitive cases. 
Full insertion of the cannula tip through the teat canal has been shown to reduce 
effectiveness of mastitis treatment. The intramammary cannula tip can transfer 
microbes from their harbour at the teat end or among keratin which lines the teat canal, 
riding into the teat cistern. The proportion of new intramammary infections induced this 
way can potentially be reduced by over 50% by only partially inserting the cannula (e.g. 
only into the distal 2-3mm of the teat canal). Damaged teat ends or teat canals are 
easily colonised by MCOs, particularly staphylococci, which can then re-infect the 
gland at any time. Partial insertion can minimise teat canal injury, and as a result, 
disturb keratin plug formation during the early dry period. Maintaining the integrity of 
the teat ends and canals is a crucial component of the defence mechanisms of the 
udder. 
Field trials with commercial antimicrobial products have demonstrated higher rates of 
mastitis cure when duration of treatment is extended past traditional convention. This is 
particularly important for the time-dependent antimicrobials. Extended treatment 
periods promote maintenance of therapeutic concentrations of antimicrobial at the 
infection site for longer. Better distribution of the antimicrobial throughout the gland 
results. Higher cure rates associated with extended treatment is likely due to extended 
contact time between the antimicrobial and MCOs7. Negative aspects of prolonged 
treatment duration include the additional costs associated with the antimicrobial 
product, extra discarded milk and labour, increased risk of introducing super-infection 
and risk of breaching withholding periods. The costs and benefits should be carefully 
considered when deciding if the extended therapy is a worthwhile option. 
Prevention: Bovine practitioners should educate their clients of the: 
 importance of treating with full dose for sufficient length of time 
 importance of proper administration of drugs (including route of administration, 
hygiene and the optimal depth of insertion of the cannula) 
 choice of route of treatment according to presenting signs 
 compatible products for combined approach, and 
 action in case of treatment failure 
The best approach to prevention of improper dose and route of administration is 
through preparing treatment protocols (e.g. standard operating procedures) made 
specifically for each farm. 
Inadequate supportive treatment 
Inflammatory change in the mammary gland can impair the drug distribution. The use 
of supportive treatment (e.g. anti-inflammatories) can decrease swelling and provide 
better distribution of the drug. In some cases, such as coliform mastitis, the supportive 
treatment is a priority to the antimicrobial treatment of mastitis. For success in treating 
mastitis associated with the ‘sick-cow-syndrome’, it is essential to have the general 
condition (e.g. shock, toxaemia, dehydration, septicaemia) of the cow addressed.  
  
 
Prevention: Bovine practitioners should educate their clients of the: 
 importance of supportive treatment for the treatment success and survival of 
any sick cattle 
The best approach to on-farm improvements to supportive treatment and care for acute 
cases is clear, easily interpreted definitions and instructions of guidelines within the 
treatment protocols. In the event of any signs of systemic infection, it should be 
standard protocol to provide parenteral therapy and pain management for promotion of 
better animal welfare, higher likelihood of therapy success and for faster recovery from 
mastitis. 
Drug factors  
Many antimicrobial, vehicle and/or formulation factors are associated with failure of the 
mastitis treatment and discussing these is out of the scope of this paper. Most of the 
factors from this group are due to the pharmacokinetic characteristics of the active and 
the effects of the formulation design on these properties. The common factors include: 
 Low bio-availability 
 Inadequate local tissue concentration  
 Weak or excessive passage of drug across the blood-milk barrier 
 High degree of milk and serum protein binding 
 Improper antimicrobial selection  
 Antagonism between concurrently used antimicrobials 
 Extent of drug dissociation in regard to milk pH and composition changes with 
mastitis 
 Short half-life of the drug 
 Side effects of the drug 
 Other factors that lead to inactivation of the antimicrobial in vivo or in vitro 
Factors related to MCOs 
Many factors related to MCOs can be the reason for mastitis treatment failure. 
Commonly listed include: 
 tissue invasive or intracellular-dwelling pathogens 
 microbial mechanisms that overcome antimicrobial effects in milk  
 drug tolerance and resistance  
 short lived mastitis-causing organisms in the mammary gland  
 microbial dormancy and metabolic state, and 
 ‘L’ form of MCOs 
Unfortunately, many of these factors are difficult to predict and control, and are little 
known about on dairy farms. 
Tissue invaders or intracellular location 
Tissue invading organisms, such as coagulase-positive staphylococci, become walled 
off in the udder parenchyma by creating thick fibrous scar tissue encapsulation within 
deep-seated abscesses. They can also gain refuge within the acid phagolysosomes of 
macrophages and neutrophils. Similarly, some strains of Str. uberis seek refuge among 
the epithelial, macrophage, and/or secretory cells of the mammary gland8. Additionally, 
chronic S. aureus infections pose therapeutic problems through promotion of localised 
avascular scar tissue, meaning that parenteral therapy probably provides little benefit 5. 
Therapy may kill the organisms that are not walled off, but at a later date, the 
organisms within the scar tissue can break out, multiply, cause additional damage to 
the udder secretory tissue and promote further formation of scar tissue. Consequently, 
  
 
when antimicrobial treatment is administered, antimicrobials cannot reach the MCOs 
and treatment failure may occur even when the organisms are susceptible to the used 
antimicrobial.  
Microbial mechanisms that overcome antimicrobial effects in milk  
Microbes often survive due to their ability to rapidly acclimatise to environmental 
conditions. Evasion strategies for escaping antimicrobial factors include encapsulation 
or slime formation, receptor-mediated absorption of host proteins, interference with 
phagocyte function, production of enzymes capable of digesting antimicrobials and 
other inherent factors. Other mechanisms include leukocidin production; adherence of 
bacteria to tissue lining the gland that results in avoidance of the wash-out effect during 
milking; buoyancy of microbes in cream, and an increase in microbial replication rate. 
These factors are additional to the drug tolerance and resistance. 
Drug tolerance and resistance 
Drug tolerance and resistance are usually characteristics of bacterial species or strains. 
Global, widespread use of antimicrobials in mastitis treatment has raised questions 
over the prevalence of antimicrobial resistance genes in mastitis-causing organisms 
flourishing in preference to ‘susceptible’ genes. Selection of therapy for resistant 
organisms may necessitate use of a different antimicrobial. Even though widely varying 
results of the efficacy of antimicrobial treatments have been reported, there is no real 
evidence that antimicrobial resistance poses an emerging crisis in bovine mastitis 
pathogenesis and treatment9, 10.  
Selecting an ineffective antimicrobial agent, such as penicillin to treat β-lactamase-
producing S. aureus or Bacteroides fragilis5 can result in treatment failure. Therefore, it 
is the opinion of the author that antimicrobial susceptibility testing should be used to 
make ‘herd profiles’ regarding resistance. The choice of an inappropriate antimicrobial 
should not be an excuse for failure of the mastitis treatment, particularly when 
antimicrobial susceptibility testing is readily available and not financially significant. 
However, due to the diverse source of MCOs, the ‘herd profile’ can have limited merit 
in a herd affected with environmental mastitis. 
Short lived mastitis-causing organisms in the mammary gland  
Some MCOs, particularly coliforms, are short lived in the mammary gland. Thus, 
antimicrobial therapy may be of secondary importance in comparison to immediate 
supportive treatment for systemic conditions (e.g. endotoxic shock). The acute illness 
that regularly accompanies mastitis caused by a coliform organism can distinguish 
them as the likely causatives, thereby guiding the actions and therapy decisions of the 
facilitated stockperson at cow-side. 
Microbial dormancy and metabolic state and ‘L’ forms 
Mastitis-causing organisms are most susceptible to antimicrobials during their 
exponential growth phase. Non-multiplying organisms are not susceptible to most 
antimicrobials due to their mode of action. All microbial populations contain some 
organisms that are not in the active growth phase, which therefore survive. Bacteria 
exposed to antimicrobials may become growth-inhibited, and can remain so for some 
time after the termination of therapy5. Low multiplication rates are also seen in 
organisms within phagocytes, particularly important for S. aureus infections.  
Sometimes certain organisms develop an acapsular ‘L’ form that is contained only in a 
cell membrane. Such L-forms are not susceptible to antimicrobials such as penicillins 
and cephalosporins that attack the cell wall, even when the drug concentrations and 
the contact time are sufficient5.  
  
 
Mammary gland factors 
Some factors related to the mammary gland itself can be the reason for mastitis 
treatment failure. Commonly listed include: 
 teat canal infections 
 trauma 
 adverse effects of treatment products 
 uneven distribution and physical obstruction of the drug within the gland 
 udder tissue necrosis 
 circulatory inhibition due to inflammation 
Unfortunately, many of these factors at the current state of knowledge and with cow-
side technology are difficult to identify, predict or control, aside from appropriate use of 
anti-inflammatories. 
Teat canal infections 
Standard methods of intramammary antimicrobial administration into a mastitis quarter 
or as dry cow therapy do not necessarily eliminate teat canal infections. MCO’s 
harboured in the teat canal serve as a potential reservoir for later infection of 
parenchyma of the mammary gland. After dispensing antimicrobial therapy into the 
gland, the resident teat canal infection may then facilitate a new, super - infection, or be 
a source for re-infection.  
Trauma and adverse effects of treatment products 
Trauma or adverse reactions associated with the therapeutic product result in 
decreased capacity of the mammary gland defences. This predisposes the quarter to 
infection or re-infection. Trauma of the teat canal and teat end has been discussed 
previously, within the management and iatrogenic factors associated with failure of 
mastitis treatment. The tissues of the mammary gland can be irritated by the 
antimicrobial or additives in the preparation, such as vehicle or thickeners. Irritation 
exacerbates the inflammatory process, and further weakens potential for distribution of 
the drug through the intricate structure of the mammary gland. Biological response to 
the antimicrobial or its vehicle can decrease defence powers of the mammary gland 
(e.g. altered oxidative ‘burst’ activity of bovine polymorph-neutrophils, resulting in their 
use as concealment by intracellular MCOs).  
Uneven distribution and physical obstruction 
In all cases of mastitis, oedema and inflammatory products obstruct the diffusion of 
antimicrobials to some extent, by compression or blockage of the milk duct system. 
Necrosis of the affected area of the gland and abscess formation also results in a 
similar effect. The diffusion of antimicrobial products throughout the gland is thereby 
impaired. For this reason, it is often very difficult to ensure that antimicrobials have 
good contact with MCOs, particularly when administered via the intramammary route6. 
It has been proposed that systemic administration of the antimicrobials may overcome 
these problems1.  
Udder tissue necrosis 
Mastitis which causes udder tissue necrosis leads to a poor blood supply to the 
affected areas, and consequently, a decreased redox potential that favours anaerobic 
MCOs. There is no effective passage of drugs into necrotic, avascular udder tissue. 
  
 
Circulatory inhibition due to inflammation 
Oedema throughout the tissues of the mammary gland can impose constriction of 
vasculature throughout the infected, mastitis udder. While all therapeutics indicated for 
systemic use against mastitis are able to cross the blood/milk barrier to some extent, 
the carriage of the drug in blood, as within the gland, becomes compromised where it is 
needed most. As a result, in the case of advanced swelling/oedema, even the 
combination of intramammary and systemic antimicrobial therapy can be ineffective.  
Herd, cow and quarter factors 
An important part of the cumulative bovine mastitis strategy, whereby we seek 
minimise the use of antimicrobials, is to refrain from treating cases with a poor 
prognosis at the outset. As discussed previously, the probability of cure can be 
estimated, and is significantly influenced by cow and quarter factors, such as: age or 
parity, number and location of quarters affected, days in milk or lactation stage, number 
of positive samples and colony-forming units prior to treatment, and somatic cell and 
dry- cow therapy history before treatment initiation.  
In general, higher parity, sustained higher somatic cell level and increased numbers of 
positive samples or colony-forming units prior to treatment are associated with a lower 
cure rate. Additionally, cure rates are lower with increased number of quarters, and 
when the rear quarters are affected.  
Significantly lower treatment success in older cows or cows of higher parity is likely due 
to morphology of the mammary gland, and decreased general resistance to infection. 
Older cows are more likely to have experienced clinical or subclinical intramammary 
infections and have changes in morphology of the mammary gland that factor for 
decreased cure rates. Older cows in general terms have larger tissue volume within 
their mammary glands compared to heifers. The extent of affected tissue is also 
greater when more than one quarter is affected, or when rear quarters are affected. 
The volume and larger mass of mammary gland can influence drug distribution and 
subsequently, the concentration of drug penetrating to the target/infection site.  
Selection of cows for treatment 
The probability of a cure can be estimated prior to treatment. There are many factors 
associated with a successful cure. The following are the most important: age, lactation 
stage, causative organism, quarter location and level of individual cow somatic cell 
count (ICSCC) history prior to initiation of the treatment. For example, Schukken et al., 
(2007) provides the following calculations: 
Scenario 1) Older cow, treated at 150 days in milk, infected with S. aureus in a hind 
quarter with a SCC of 2,000,000 cells/mL has approximately 1% chance of cure. 
Estimated probability to cure = (1/1[1 + exp (-1 x (0.40-1.25-1.05-1.53-0.95))] = 1% 
Scenario 2) Heifer, treated at 220 days in milk, infected with S. aureus in a front 
quarter with a SCC of 500,000 cells/mL has approximately 61% chance of cure. 
Estimated probability to cure = (1/1[1 + exp (-1 x (0.40))] = 61% 
(Calculations reproduced with permission from the author – 11th April 2007) 
A similar predictive model is described by Bradley et al., (2005) in the New Zealand 
Veterinary Association, Dairy Cattle Veterinarians Proceedings (available on-line for 
AVA members) to aid in the decision to treat sub-clinical mastitis. 
Prediction of the probability of cure is vastly underutilised by pharmaceutical 
companies, farmers and veterinarians alike in the identification of the most suitable 
candidate animals for therapy. As a result, appropriate culling decisions regarding cows 
  
 
with an incidence of lactational infection has been a sub-optimally employed 
management tool in practice4, 10. 
Cow’s general condition 
Sick or dehydrated cattle are prone to have reduced circulation.  This can have an 
effect on the normal course of systemic distribution of drugs and the rate of elimination 
of drugs. Thereby, overt illness can result in prolonged duration of detectable levels of 
the drugs in tissue and milk. 
Previous mastitis history 
Cows that have suffered previous mastitis episodes are at increased risk of re-
occurrence and generally have lower treatment success rates. Reasons for this 
increased risk include changes to defence mechanisms of the mammary gland.  There 
is increased probability of chronic changes within the udder, resulting in weakened 
vascularisation and consequently, impaired drug distribution. 
Herd level factors 
Additional factors associated with bovine mastitis treatment failure include some herd 
level variables such as hygiene, drug storage conditions, bulk milk somatic cell count 
level, number of new infections as judged by increase in somatic cell count and 
observed prevalence of S. aureus in the herd. In herds with high prevalence of S. 
aureus infection the risk of new intramammary infections or reinfection is higher. 
Prevention: Bovine practitioners should educate clients in regard to: 
 Best-practice selection of cows for treatment or culling 
 Identifying and avoiding treatment of teat canal infections 
 Appropriate storage conditions for drugs 
 Role of general management practices in reducing mastitis incidence 
 Impacts of high mastitis prevalence, and 
 Importance of the incidence of new infections as related to treatment outcomes. 
Conclusion 
Failure of mastitis treatment is a common problem in clinical practice. It is associated 
with the following groups of factors: management-, iatrogenic-, drug-, mastitis-causing 
organism-, and mammary gland-related factors. Strategy gaps associated with any of 
these factors results in inappropriate therapy via choice of antimicrobial, inadequate 
concentration of antimicrobial at the site of infection, and/or an inadequate at-
concentration duration than required. Additionally, herd, cow and quarter level factors 
can also affect the reliability of successful treatment of bovine mastitis. Treating cases 
with a poor prognosis will increase the risk of treatment failure.  
Veterinarians should take an active role in the education of farmers in the treatment 
and management of bovine mastitis. Management and iatrogenic factors can be easily 
influenced. The value of veterinarians fostering good communication and promoting 
approachability in this regard cannot be underestimated. 
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